Why it matters: The NHS has committed to reducing its carbon footprint by 80% by 2028 to 2032, including a shift to lower carbon inhalers. Dry powder inhalers (DPIs) and other newer types of inhalers like soft mist inhalers are less harmful to the environment than traditional metered dose inhalers (MDIs).
The 2022-2023 PCN Investment and Impact Fund (IIF) includes an indicator focusing on the percentage of non-salbutamol MDI prescriptions issued. NHSE England’s aim is that, in line with best practice in other European countries, by 2023/24 only 25% of non-salbutamol inhalers prescribed will be MDIs.
NICE has produced a inhaler decision aid to facilitiate discussion about inhaler options.
Please note: as prescribing data does not contain patient information, this measure uses prescription items for all ages. This indicator is also calculated using items issued rather than prescriptions issued. The data shown will therefore not exactly match the IIF indicator.
Description: MDIs prescribed as a proportion of all inhalers in BNF Chapter 3, excluding salbutamol
Tagged as: Standard, Greener NHS, NHS England Investment and Impact Fund, NICE, Respiratory (or browse all measures)
Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.
View measure for NHS England combined →